Abstract
David McCall, Editor, Cell & Gene Therapy Insights, talks to Riccardo Biavasco, Senior Scientist at bluebird bioRiccardo Biavasco obtained his PhD in Cellular and Molecular Biology in 2018 working at the Telethon Institute for Gene Therapy, where he designed and generated a humanized mouse model for myeloid inflammatory neoplasms and characterized the effects of aberrant cellular senescence in hematopoietic stem and progenitor cells. In 2019 Riccardo joined bluebird bio analytical development group, where he coordinates the development of characterization assays for hematopoietic stem cell drug products and he is responsible for the interactions with regulatory agencies regarding drug product characterization assays. 
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
